Deep Science Ventures
ABOUT DSV Deep Science Ventures is creating a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures. We operate in 4 sectors: Pharmaceuticals, Climate, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions. OUR PARTNERSHIP WITH GENERAL INCEPTION Driven by mutual conviction in the huge unmet medical need in fibrotic diseases, DSV has partnered with General Inception to accelerate the development of novel therapeutics, jointly building a new venture solely dedicated to anti-fibrotic therapies. To maximise impact and exploit synergies across both organisations, we are forging a new venture creation model which combines DSV's innovative first-principles venture creation methodology with General Inception's deep domain expertise, network and portfolio - leveraging the best of both. To learn more about the partnership, please see our Press Release , and to learn more about General Inception ABOUT THE ROLE We are looking for future Founders: entrepreneurially-minded individuals with deep technical and commercial domain expertise, who are eager to solve urgent unmet challenges through venture building. This role offers a unique opportunity to work at the forefront of fibrosis drug development, leading a company solving challenges in immune resolution and myeloid reprogramming to reverse disease. You will join DSV's venture creation programme as a Founder-in-Residence and work closely with the DSV and GI team to spin out the new company. During the programme you will refine, improve and complement existing scoping work on: Fundraising strategy & pitching Clinical strategy & positioning Commercial neglect (IP strategy, differentiation, competition) Value proposition (market, value capture, techno-economics) Optimising company strategy for the most rapid and derisked path to Series A (within 18-24 months from launch) Preparation for Investment Committee will involve fulfilling any outstanding investment criteria, recruiting advisory and co-founding team members, and parallel fundraising for additional expansion funds. Assuming success at both respective Investment Committees, you will receive pre-seed investment from DSV and GI, and spinout the company in Q4 2025. You and your co-founders will own a significant stake in the business and continue receiving support post-spinout. THE OPPORTUNITY Fibrosis underlies a staggering proportion of human diseases, accounting for 18% of all global deaths (35% including solid tumours), with increasing prevalence worldwide, and consistent market growth across almost all indications. Yet there are still only two FDA-approved anti-fibrotic drugs - marketed for lung fibrosis alone - neither of which are able to meaningfully halt disease, let alone reverse it. The unmet medical need is therefore enormous. But competition in the development pipeline is increasingly fierce for liver and lung fibrosis, and many clinical approaches have historically proven to be intractable at reversing disease, teaching us valuable biological lessons that must be incorporated for the next generation of therapeutics. To reverse disease, we must directly or indirectly achieve multiple biological outcomes - manipulating pathogenic myofibroblasts, resolving pro-fibrotic inflammation, regenerating healthy epithelia & endothelia, degrading existing ECM deposits, and ideally neutralising (reactivity to) any upstream triggers. We believe we have identified approaches that may be able to address many if not all of these outcomes, by focussing on pro-resolution mechanisms and immune reprogramming. Our ambition is to create impactful new medicines that have (i) transformative mono-therapeutic efficacy, (ii) applicability across multiple fibrotic diseases (beyond the lung), (iii) complementary yet distinct mechanism of action compared to standard-of-care medicines (to ensure combinability with future clinical regimens), and (iv) conveniently and/or infrequently administered (to ensure patient convenience and low burden on healthcare systems). To this end, we are pursuing a multi-strategy portfolio of approaches within immune resolution and myeloid reprogramming that balance ambition, derisking, speed, and optionality, while maintaining focus on key biology areas where we can develop deep expertise and know-how. Our existing strategy involves generation of proprietary assets/IP whilst derisking multiple in-licensing opportunities in parallel that could substantially accelerate the company's trajectory. This will require a talented and experienced leader with commercial knowhow to joining the Founding team. We believe now is the time to turn this vision into a reality. Will you join us to lead the effort? WHO SHOULD APPLY We are looking for an exceptional individual with the following: Essential Values You are highly motivated by unsolved challenges in fibrotic disease, and driven to challenge the status quo of how we treat these underserved patients. You are impact driven, take the initiative, make things happen, and think from a first principles perspective to figure out what's really needed. You have clear entrepreneurial spirit and mindset, demonstrated through impactful innovation, and an ability to work in ambiguous, unstructured but fast-paced, demanding and pressurised environments. Collaborative nature, with the ability to work effectively in cross-functional teams. Essential experience (must-have) You have translational R&D experience in inflammatory, autoimmune or fibrotic disease. Analogous experience in similar diseases/cells/tissues/mechanisms such as fibroblast-targeting in solid tumours is also acceptable. You have 15+ years drug development experience in pharma/biotech and/or BD/corporate development experience. We are also open to life science VC investors with strong operational drug development experience. You have deep commercial & strategic expertise in therapeutic development, demonstrated through successful; (a) VC fundraising (ideally at Series A or Seed), OR, (b) execution of deals (licensing, partnering, collaborations) or transactions (M&A, IPO). A strong existing network of investor & pharma BD/CVC relationships is highly preferred. Strong track record of building and leading successful teams, ideally with experience integrating in-house operations with outsourced relationships (CROs and/or academic collaborators). Preferred experience (nice-to-have) Previous CEO experience (in biotech) Previous Founder experience (in biotech) Technical or clinical development experience in protein therapeutics and/or bispecific antibodies Technical or clinical development experience in lung, kidney, liver, or heart fibrosis. Deep technical experience in fibrotic disease biology Track record of successful non-dilutive (grant) fundraising Track record of high quality publications or thought leadership in the field OUR OFFER By joining DSV, you'll be joining a team of operators who have founded companies and led translation of science at some of the most respected universities, charities, funds and government agencies. 2/3 of the team have founded or led a company at C-suite and 65% have a PhD. Our team dedicate several hours every week to each Founder or founding team to provide tailored guidance, resources and feedback covering every aspect of what it takes to successfully launch a new venture from both the tech and commercial perspectives: We provide optimised, purpose-built, proprietary tools, resources and processes to help create high-impact ventures from scratch, using our venture creation methodology . General Inception's extensive network (investors, clinicians, academics), technical domain expertise, and wide-ranging portfolio company capabilities across tools, platforms, diagnostics and therapeutics. DSV's network of Partners, Advisors, Community and Pharma Scientific Advisory Board members - including leaders of therapeutics VCs, Pharma BD execs, C-suite operators at leading biotech companies, venture builders, and CDMOs, from whom you will receive detailed feedback. We jointly provide an initial £250k ( $340k / €290k) investment governed by our Investment Committee to incorporate the new venture and develop early proof-of-concept data that is often needed to attract high profile non-venture studio VCs. This funding is also key for obtaining grant funding, which often needs to be matched with private investment. Note: we will fundraise in parallel (pre-launch) to provide additional 'expansion' financing at or shortly after company launch. In this case, with the maturity of the targets, assets and in-licensing opportunities, we anticipate that an acceleratedSeed round may also be possible. Our plan is to nominate a development candidate within 12-18 months of launch (but exact timelines will depend on various factors). You and your co-founder(s) will own a significant equity stake in the company. We provide minimum guaranteed income of £4 . click apply for full job details
ABOUT DSV Deep Science Ventures is creating a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures. We operate in 4 sectors: Pharmaceuticals, Climate, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions. OUR PARTNERSHIP WITH GENERAL INCEPTION Driven by mutual conviction in the huge unmet medical need in fibrotic diseases, DSV has partnered with General Inception to accelerate the development of novel therapeutics, jointly building a new venture solely dedicated to anti-fibrotic therapies. To maximise impact and exploit synergies across both organisations, we are forging a new venture creation model which combines DSV's innovative first-principles venture creation methodology with General Inception's deep domain expertise, network and portfolio - leveraging the best of both. To learn more about the partnership, please see our Press Release , and to learn more about General Inception ABOUT THE ROLE We are looking for future Founders: entrepreneurially-minded individuals with deep technical and commercial domain expertise, who are eager to solve urgent unmet challenges through venture building. This role offers a unique opportunity to work at the forefront of fibrosis drug development, leading a company solving challenges in immune resolution and myeloid reprogramming to reverse disease. You will join DSV's venture creation programme as a Founder-in-Residence and work closely with the DSV and GI team to spin out the new company. During the programme you will refine, improve and complement existing scoping work on: Fundraising strategy & pitching Clinical strategy & positioning Commercial neglect (IP strategy, differentiation, competition) Value proposition (market, value capture, techno-economics) Optimising company strategy for the most rapid and derisked path to Series A (within 18-24 months from launch) Preparation for Investment Committee will involve fulfilling any outstanding investment criteria, recruiting advisory and co-founding team members, and parallel fundraising for additional expansion funds. Assuming success at both respective Investment Committees, you will receive pre-seed investment from DSV and GI, and spinout the company in Q4 2025. You and your co-founders will own a significant stake in the business and continue receiving support post-spinout. THE OPPORTUNITY Fibrosis underlies a staggering proportion of human diseases, accounting for 18% of all global deaths (35% including solid tumours), with increasing prevalence worldwide, and consistent market growth across almost all indications. Yet there are still only two FDA-approved anti-fibrotic drugs - marketed for lung fibrosis alone - neither of which are able to meaningfully halt disease, let alone reverse it. The unmet medical need is therefore enormous. But competition in the development pipeline is increasingly fierce for liver and lung fibrosis, and many clinical approaches have historically proven to be intractable at reversing disease, teaching us valuable biological lessons that must be incorporated for the next generation of therapeutics. To reverse disease, we must directly or indirectly achieve multiple biological outcomes - manipulating pathogenic myofibroblasts, resolving pro-fibrotic inflammation, regenerating healthy epithelia & endothelia, degrading existing ECM deposits, and ideally neutralising (reactivity to) any upstream triggers. We believe we have identified approaches that may be able to address many if not all of these outcomes, by focussing on pro-resolution mechanisms and immune reprogramming. Our ambition is to create impactful new medicines that have (i) transformative mono-therapeutic efficacy, (ii) applicability across multiple fibrotic diseases (beyond the lung), (iii) complementary yet distinct mechanism of action compared to standard-of-care medicines (to ensure combinability with future clinical regimens), and (iv) conveniently and/or infrequently administered (to ensure patient convenience and low burden on healthcare systems). To this end, we are pursuing a multi-strategy portfolio of approaches within immune resolution and myeloid reprogramming that balance ambition, derisking, speed, and optionality, while maintaining focus on key biology areas where we can develop deep expertise and know-how. Our existing strategy involves generation of proprietary assets/IP whilst derisking multiple in-licensing opportunities in parallel that could substantially accelerate the company's trajectory. This will require a talented and experienced leader with commercial knowhow to joining the Founding team. We believe now is the time to turn this vision into a reality. Will you join us to lead the effort? WHO SHOULD APPLY We are looking for an exceptional individual with the following: Essential Values You are highly motivated by unsolved challenges in fibrotic disease, and driven to challenge the status quo of how we treat these underserved patients. You are impact driven, take the initiative, make things happen, and think from a first principles perspective to figure out what's really needed. You have clear entrepreneurial spirit and mindset, demonstrated through impactful innovation, and an ability to work in ambiguous, unstructured but fast-paced, demanding and pressurised environments. Collaborative nature, with the ability to work effectively in cross-functional teams. Essential experience (must-have) You have translational R&D experience in inflammatory, autoimmune or fibrotic disease. Analogous experience in similar diseases/cells/tissues/mechanisms such as fibroblast-targeting in solid tumours is also acceptable. You have 15+ years drug development experience in pharma/biotech and/or BD/corporate development experience. We are also open to life science VC investors with strong operational drug development experience. You have deep commercial & strategic expertise in therapeutic development, demonstrated through successful; (a) VC fundraising (ideally at Series A or Seed), OR, (b) execution of deals (licensing, partnering, collaborations) or transactions (M&A, IPO). A strong existing network of investor & pharma BD/CVC relationships is highly preferred. Strong track record of building and leading successful teams, ideally with experience integrating in-house operations with outsourced relationships (CROs and/or academic collaborators). Preferred experience (nice-to-have) Previous CEO experience (in biotech) Previous Founder experience (in biotech) Technical or clinical development experience in protein therapeutics and/or bispecific antibodies Technical or clinical development experience in lung, kidney, liver, or heart fibrosis. Deep technical experience in fibrotic disease biology Track record of successful non-dilutive (grant) fundraising Track record of high quality publications or thought leadership in the field OUR OFFER By joining DSV, you'll be joining a team of operators who have founded companies and led translation of science at some of the most respected universities, charities, funds and government agencies. 2/3 of the team have founded or led a company at C-suite and 65% have a PhD. Our team dedicate several hours every week to each Founder or founding team to provide tailored guidance, resources and feedback covering every aspect of what it takes to successfully launch a new venture from both the tech and commercial perspectives: We provide optimised, purpose-built, proprietary tools, resources and processes to help create high-impact ventures from scratch, using our venture creation methodology . General Inception's extensive network (investors, clinicians, academics), technical domain expertise, and wide-ranging portfolio company capabilities across tools, platforms, diagnostics and therapeutics. DSV's network of Partners, Advisors, Community and Pharma Scientific Advisory Board members - including leaders of therapeutics VCs, Pharma BD execs, C-suite operators at leading biotech companies, venture builders, and CDMOs, from whom you will receive detailed feedback. We jointly provide an initial £250k ( $340k / €290k) investment governed by our Investment Committee to incorporate the new venture and develop early proof-of-concept data that is often needed to attract high profile non-venture studio VCs. This funding is also key for obtaining grant funding, which often needs to be matched with private investment. Note: we will fundraise in parallel (pre-launch) to provide additional 'expansion' financing at or shortly after company launch. In this case, with the maturity of the targets, assets and in-licensing opportunities, we anticipate that an acceleratedSeed round may also be possible. Our plan is to nominate a development candidate within 12-18 months of launch (but exact timelines will depend on various factors). You and your co-founder(s) will own a significant equity stake in the company. We provide minimum guaranteed income of £4 . click apply for full job details
Deep Science Ventures
ABOUT THE ROLE At DSV we're looking for future Founders, entrepreneurially minded individuals with industry-specific technical and commercial domain expertise eager to solve urgent unmet challenges through venture building. You will join DSV's venture creation programme as a Founder in Residence and work closely with the DSV team, using our methodology , to spin-out a new company. During the programme, you'll work on all aspects related to venture creation in this opportunity area, including working out the optimal approach to solve for the desired outcome, building a team and building a viable business case. Once the new venture is incorporated with pre-seed investment from DSV, you and your co-founders will own the majority stake in the business and continue receiving support from the DSV team post-spinout. The role is full-time, fully remote until venture incorporation and spin-out, after - TBD. THE OPPORTUNITY AREA Over 6 million individuals live with Parkinson's disease (PD) today, and this number is projected to reach 12 million globally by 2040 as populations age. Whilst current therapies do offer symptomatic relief from debilitating motor symptoms, no clinically approved drug intervenes at root cause, meaning disease progression cannot be prevented. In addition, emerging therapeutics which show great promise in animal models of PD often fail to translate in the clinical setting, with even the most successful clinical trials reporting incremental benefit, often capped by dose limiting toxicity. To address this, we are partnering with Parkinson's UK to develop precise, next generation therapies which target true disease modifying nodes in previously unimagined ways. As PD is a multi-pathway pathology, spanning oxidative stress, impaired autophagy, mitochondrial dysfunction and neuroinflammation, the efficacy of single pathway approaches is constrained. OUR APPROACH We are designing a therapeutic approach that will target master homeostatic regulators which can simultaneously correct numerous PD pathways, changing the course of disease. We believe this has the potential to transform patient lives by slowing, halting or even reversing disease progression. This pathway has been the focus of drug development in the past but not been drugged successfully through classic approaches. We are looking to unlock this through the use of novel modalities and a clever target selection and targeting strategy that has the potential to overcome the many feedback looks regulating this pathway. WHO SHOULD APPLY Essential (must-have): PhD in neuroscience or other field relevant to the project; Extensive, systems-level knowledge of Parkinson's disease, including at the cellular and molecular level; Expertise in oxidative stress and/or neuroprotective pathways; Experience in cellular, molecular and/or biochemical approaches to drug discovery for CNS disorders; Experience working in biotech/pharma or an alternative setting which requires strong commercial awareness and understanding of the drug development process; Entrepreneurial spirit, likely demonstrated through impactful innovation; You are innovative, creative, and guided by first-principles thinking; You are highly motivated to create curative solutions for PD patients. Preferred (nice-to-have): Broad knowledge of brain-specific drug delivery techniques; Experience in nucleic acid based payloads (ASO/siRNA/DNA) and delivery techniques; Track record of high quality publications in the field, or thought leadership in the field; High level industry experience in either pharma, biotech, scientific start-ups, life sciences consulting, life sciences VC, or have previously been an inventor/contributor on patents, etc.; Fundraising experience at seed and Series A stages, with established investor contacts. OUR OFFER By joining DSV, you'll be joining a team of operators who have founded companies and led translation of science at some of the most respected universities, charities, funds and government agencies. 2/3 of the team have founded or led a company at C-suite and 65% have a PhD. Our team dedicate several hours every week to each Founder/founding team to provide tailored guidance, resources and feedback covering every aspect of what it takes to successfully launch a new venture from both the tech and commercial perspectives: We provide optimised, purpose-built, proprietary tools, resources and processes to help create high-impact ventures from scratch, using our venture creation methodology; We draw on opportunity area specific know-how provided by our Partner organisation - Parkinson's UK - working collaboratively with their team of experts and Advisors; We provide £250k launch investment (subject to Investment Committee approval) to incorporate the new venture and develop early proof-of-concept data that's needed to attract high profile VCs as well as non-dilutive grant funding; We provide guaranteed income of £4,166 per month paid to each Founder-in-Residence as a fixed consultancy fee until the company is launched and the pre-seed investment is secured; You and the current Founder-in-Residence, together with any additional co-founders, will collectively own a majority equity stake in the company; We provide continuous support after post spin-out, including fundraising, commercial partnerships, recruitment and team-building (amongst other things); plus There are dozens of Founders currently at DSV across sectors working collaboratively and supporting one another - a unique resource to draw on. WHO YOU'LL BE JOINING You will be joining Dr. Kiren Baines-Mortimore, an accomplished scientific leader with many years of experience across drug discovery and development. Kiren, is the former co-founder and CSO at Extracellular, a cultivated meat CDMO. Prior to founding Extracellular, Kiren was the Analytical Development and Quality Control Lead at eXmoor Pharma,where she supported clients in the cell and gene therapy sector with process and analytical development, manufacturing, and commercialization. Earlier in her career, Kiren contributed to drug discovery initiatives at Charles River Laboratories. Kiren earned her PhD in Cell Biology from the University of Bristol. Kiren's background in Parkinson's combined with her expertise in drug development, along with her outstanding professionalism and ambition, makes her a top talent to work with. ABOUT DSV Deep Science Ventures is creating a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures. We operate in 4 sectors: Pharmaceuticals, Climate, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions. ABOUT OUR PARTNERSHIP WITH PARKINSON'S UK In a landmark collaboration that marries scientific prowess with an unwavering dedication to improving patient lives, Deep Science Ventures, an avant-garde venture creator headquartered in London, has announced a pioneering partnership with Parkinson's UK , the leading charity driving better care, treatments, and quality of life for those affected by Parkinson's. This strategic alliance is set to merge DSV's unique invention method with Parkinson's UK's rich insights into patient care, igniting the creation of a new, dedicated company. The aim is to propel the most innovative and efficient therapeutic approach into real-world application, funded by the transformative Parkinson's Virtual Biotech initiative - Parkinson's UK investment arm.
ABOUT THE ROLE At DSV we're looking for future Founders, entrepreneurially minded individuals with industry-specific technical and commercial domain expertise eager to solve urgent unmet challenges through venture building. You will join DSV's venture creation programme as a Founder in Residence and work closely with the DSV team, using our methodology , to spin-out a new company. During the programme, you'll work on all aspects related to venture creation in this opportunity area, including working out the optimal approach to solve for the desired outcome, building a team and building a viable business case. Once the new venture is incorporated with pre-seed investment from DSV, you and your co-founders will own the majority stake in the business and continue receiving support from the DSV team post-spinout. The role is full-time, fully remote until venture incorporation and spin-out, after - TBD. THE OPPORTUNITY AREA Over 6 million individuals live with Parkinson's disease (PD) today, and this number is projected to reach 12 million globally by 2040 as populations age. Whilst current therapies do offer symptomatic relief from debilitating motor symptoms, no clinically approved drug intervenes at root cause, meaning disease progression cannot be prevented. In addition, emerging therapeutics which show great promise in animal models of PD often fail to translate in the clinical setting, with even the most successful clinical trials reporting incremental benefit, often capped by dose limiting toxicity. To address this, we are partnering with Parkinson's UK to develop precise, next generation therapies which target true disease modifying nodes in previously unimagined ways. As PD is a multi-pathway pathology, spanning oxidative stress, impaired autophagy, mitochondrial dysfunction and neuroinflammation, the efficacy of single pathway approaches is constrained. OUR APPROACH We are designing a therapeutic approach that will target master homeostatic regulators which can simultaneously correct numerous PD pathways, changing the course of disease. We believe this has the potential to transform patient lives by slowing, halting or even reversing disease progression. This pathway has been the focus of drug development in the past but not been drugged successfully through classic approaches. We are looking to unlock this through the use of novel modalities and a clever target selection and targeting strategy that has the potential to overcome the many feedback looks regulating this pathway. WHO SHOULD APPLY Essential (must-have): PhD in neuroscience or other field relevant to the project; Extensive, systems-level knowledge of Parkinson's disease, including at the cellular and molecular level; Expertise in oxidative stress and/or neuroprotective pathways; Experience in cellular, molecular and/or biochemical approaches to drug discovery for CNS disorders; Experience working in biotech/pharma or an alternative setting which requires strong commercial awareness and understanding of the drug development process; Entrepreneurial spirit, likely demonstrated through impactful innovation; You are innovative, creative, and guided by first-principles thinking; You are highly motivated to create curative solutions for PD patients. Preferred (nice-to-have): Broad knowledge of brain-specific drug delivery techniques; Experience in nucleic acid based payloads (ASO/siRNA/DNA) and delivery techniques; Track record of high quality publications in the field, or thought leadership in the field; High level industry experience in either pharma, biotech, scientific start-ups, life sciences consulting, life sciences VC, or have previously been an inventor/contributor on patents, etc.; Fundraising experience at seed and Series A stages, with established investor contacts. OUR OFFER By joining DSV, you'll be joining a team of operators who have founded companies and led translation of science at some of the most respected universities, charities, funds and government agencies. 2/3 of the team have founded or led a company at C-suite and 65% have a PhD. Our team dedicate several hours every week to each Founder/founding team to provide tailored guidance, resources and feedback covering every aspect of what it takes to successfully launch a new venture from both the tech and commercial perspectives: We provide optimised, purpose-built, proprietary tools, resources and processes to help create high-impact ventures from scratch, using our venture creation methodology; We draw on opportunity area specific know-how provided by our Partner organisation - Parkinson's UK - working collaboratively with their team of experts and Advisors; We provide £250k launch investment (subject to Investment Committee approval) to incorporate the new venture and develop early proof-of-concept data that's needed to attract high profile VCs as well as non-dilutive grant funding; We provide guaranteed income of £4,166 per month paid to each Founder-in-Residence as a fixed consultancy fee until the company is launched and the pre-seed investment is secured; You and the current Founder-in-Residence, together with any additional co-founders, will collectively own a majority equity stake in the company; We provide continuous support after post spin-out, including fundraising, commercial partnerships, recruitment and team-building (amongst other things); plus There are dozens of Founders currently at DSV across sectors working collaboratively and supporting one another - a unique resource to draw on. WHO YOU'LL BE JOINING You will be joining Dr. Kiren Baines-Mortimore, an accomplished scientific leader with many years of experience across drug discovery and development. Kiren, is the former co-founder and CSO at Extracellular, a cultivated meat CDMO. Prior to founding Extracellular, Kiren was the Analytical Development and Quality Control Lead at eXmoor Pharma,where she supported clients in the cell and gene therapy sector with process and analytical development, manufacturing, and commercialization. Earlier in her career, Kiren contributed to drug discovery initiatives at Charles River Laboratories. Kiren earned her PhD in Cell Biology from the University of Bristol. Kiren's background in Parkinson's combined with her expertise in drug development, along with her outstanding professionalism and ambition, makes her a top talent to work with. ABOUT DSV Deep Science Ventures is creating a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures. We operate in 4 sectors: Pharmaceuticals, Climate, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions. ABOUT OUR PARTNERSHIP WITH PARKINSON'S UK In a landmark collaboration that marries scientific prowess with an unwavering dedication to improving patient lives, Deep Science Ventures, an avant-garde venture creator headquartered in London, has announced a pioneering partnership with Parkinson's UK , the leading charity driving better care, treatments, and quality of life for those affected by Parkinson's. This strategic alliance is set to merge DSV's unique invention method with Parkinson's UK's rich insights into patient care, igniting the creation of a new, dedicated company. The aim is to propel the most innovative and efficient therapeutic approach into real-world application, funded by the transformative Parkinson's Virtual Biotech initiative - Parkinson's UK investment arm.